INSULIN DERIVATIVE
Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insuli...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
29.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities. |
---|---|
Bibliography: | Application Number: EP20200910739 |